AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE

EMERYVILLE, Calif. and CULVER CITY, Calif.: EMERYVILLE, Calif. and CULVER CITY, Calif., Jan. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Marketâ„¢ operating platform, and ImmunityBio (Nasdaq: IBRX), a clinical-stage immunotherapy company, today announced the completion of...

Click to view original post